Serina Therapeutics, Inc. entered into an Amended and Restated Employment Agreement with CEO Steve Ledger on July 19, 2026. Under the new terms, Mr. Ledger will receive an annual base salary of $500,000 and a target annual bonus of 50% of his base salary. The agreement outlines specific severance packages for termination without cause or resignation for good reason, including enhanced payouts and accelerated equity vesting in the event of a Change in Control. The contract also includes two-year non-competition and 18-month non-solicitation covenants. Serina Therapeutics is a biotechnology company focused on developing therapeutic solutions.
